Prescribing Trends of the Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors Among Different Physician Specialties in Canada (2015-2021).

Published:November 08, 2022DOI:
      This paper is only available as a PDF. To read, Please Download here.



      Landmark clinical trials have shown the sodium glucose cotransporter-2 (SGLT-2) Inhibitors to have cardiorenal benefits beyond their glucose lowering effect. Clinical guidelines now recommend their use in patients with chronic kidney disease or heart failure, with or without type 2 diabetes, potentially affecting prescribing patterns among physician specialties.


      Using monthly projected total retail dispensed prescription data from IQVIA’s CompuScript® database, we assessed trends in prescribing SGLT-2 inhibitors among six prescriber specialities from 2015 to 2021 in Canada. We assessed these trends at the class, agent, and dose level using joinpoint regression.


      From 2015 to 2021, the projected total retail dispensed prescriptions of SGLT-2 inhibitors from all prescribers increased. Relative to other prescribers, >60% of SGLT-2 inhibitor prescriptions were written by general practitioners or family physicians. The percentage of prescriptions from endocrinologists decreased (average annual percent change, 95%CI= -10.8, -12.2 to -9.4), while a dramatic increase was observed for cardiologists (44.1, 32.9 to 56.2). The percentage from nephrologists also increased, albeit not statistically significant (12.4, -0.5 to 27.1). Significant changes in the agent and dose of SGLT-2 inhibitor prescribed were also observed among cardiologists and nephrologists.


      Between 2015 and 2021, there was a steady increase in the proportion of SGLT-2 inhibitors prescriptions from cardiologists and nephrologists, reflecting emerging evidence and guideline recommendations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect